

## REMARKS

### Interview request

Applicants respectfully request a telephonic interview after the Examiner has reviewed the instant response and amendment. Applicants request the Examiner call Applicants' representative at (858) 720-5133.

### Status of the Claims

#### *Pending claims*

Claims 1 to 30, 33 to 64, 66 to 71 and 83 to 99 are pending and under consideration.

#### *Claims canceled in the instant amendment*

Claims 46, 51, 54, 91, 92, 95 and 96 are canceled without prejudice or disclaimer. Thus, after entry of the instant amendment, claims 1 to 30, 33 to 45, 47 to 50, 52, 53, 55 to 64, 66 to 71, 83 to 90, 93, 94, and 97 to 99, will be pending and under consideration.

#### *Outstanding Rejections*

Claims 1 to 30, 33 to 64, 66 to 71 and 83 to 99 stand rejected under 35 U.S.C. § 112, first paragraph, written description requirement. Applicants respectfully traverse all outstanding objections to the specification and rejection of the claims.

### Support for the Claim Amendments

The specification sets forth an extensive description of the invention in the amended claims. Accordingly, no new matter has been added and the amendment can be properly entered.

### Rejection Under 35 U.S.C. § 112, First Paragraph, Written Description

Claims 1 to 30, 33 to 64, 66 to 71 and 83 to 99 stand rejected under 35 U.S.C. § 112, first paragraph, as allegedly containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. In particular, it is alleged, inter alia, that the specification fails to describe a representative number of species of the genera of (1) cell surface binding molecules, or (2) cell types, as discussed on pages 2 to 5, of the OA.

Applicants respectfully traverse, and incorporate their comments from their earlier response (of July, 2006), expressly incorporated herein.

However, to expedite prosecution and facilitate allowance of this application and to address the Office's concerns, the claims have been further amended and narrowed in scope; after entry of the instant amendment they will be directed to, inter alia, methods for stable transduction of primary T cells and/or T cell stem cells comprising contacting the surface of these cells at the same time *in vitro* or *ex vivo* with both a lentiviral vector and at least one polypeptide ~~molecule~~ which binds said cell surface by binding to a T cell surface receptor.

If this amendment does not address all of the Office's concerns, Applicants respectfully request a telephonic interview to discuss these issues.

CONCLUSION

Applicants respectfully submit that after entry of the instant amendment all claims pending in this application are in condition for allowance. Applicants respectfully request withdrawal of the rejection under section 112, first paragraph. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 397272000401. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

As noted above, Applicants have requested a telephone conference with the undersigned representative to expedite prosecution of this application. After the Examiner has reviewed the instant response and amendment, please telephone the undersigned at (858) 720-5133.

Dated: February 20, 2007

Respectfully submitted,

By: /Gregory P. Einhorn/  
Gregory P. Einhorn  
Registration No.: 38,440  
MORRISON & FOERSTER LLP  
3811 Valley Centre Drive, Suite 500  
San Diego, California 92130-2332  
direct dial 858 720 5133  
general office 858 720 5100  
fax direct 858 523 5933  
fax office 858 720 5125  
Email: geinhorn@mofo.com